Fri, 16 August 2013
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
Direct download: GRACEcast-165_Lung-Audio_ASCO_2013_Veristrat_PROSE.mp3
Category:Lung-Cancer-Audio -- posted at: 2:18pm PDT